You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD30-negative

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 13, 2023

Germ Cell Tumor, Nonseminomatous Germ Cell Tumor Trial in Chapel Hill (ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine)

Recruiting
  • Germ Cell Tumor
  • Nonseminomatous Germ Cell Tumor
  • ATLCAR.CD30 Cells
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 13, 2022

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases Trial in Chapel Hill (ATLCAR.CD30 cells)

Recruiting
  • Lymphoma
  • +7 more
  • ATLCAR.CD30 cells
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022

Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • GEN3017
  • (no location specified)
Aug 25, 2023

Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Duarte, California
  • +3 more
Jul 21, 2022

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)

Recruiting
  • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
  • Classical Hodgkin Lymphoma
  • CD30.CAR-EBVST cells
  • Houston, Texas
  • +1 more
Jul 20, 2022

Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)

Not yet recruiting
  • Lymphoma
  • Brentuximab Vedotin
  • +3 more
  • Beijing, China
  • +15 more
Jan 4, 2023

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma Trial in United States

Recruiting
  • Angioimmunoblastic T-cell Lymphoma
  • +6 more
  • Los Angeles, California
  • +20 more
Aug 2, 2022

Lymphoma, Relapse/Recurrence Trial in Wuhan, Nanchang (CD30 CAR-T, Camrelizumab)

Recruiting
  • Lymphoma
  • Relapse/Recurrence
  • Wuhan, Hubei, China
  • +1 more
Apr 8, 2022

Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

Not yet recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Peripheral T Cell Lymphoma
  • (no location specified)
May 30, 2023

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

Hodgkin Lymphoma Trial in Valhalla (Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning)

Active, not recruiting
  • Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +2 more
  • Valhalla, New York
    New York Medical College
Oct 24, 2022

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Peripheral T Cell Lymphoma Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 T cells, Bendamustine, Fludarabine)

Recruiting
  • Peripheral T Cell Lymphoma
  • ATLCAR.CD30 T cells
  • +3 more
  • Chapel Hill, North Carolina
  • +1 more
Mar 4, 2022

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma Trial in Chapel Hill, Houston (CAR.CD30 T cells)

Active, not recruiting
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Lymphoma
  • CAR.CD30 T cells
  • Chapel Hill, North Carolina
  • +2 more
Mar 16, 2022

A Study of People With CD30 Positive Lymphoma in China

Not yet recruiting
  • Lymphoma
    • (no location specified)
    Aug 17, 2022

    Hodgkin Lymphoma, NK/T Cell Lymphoma, Peripheral T Cell Lymphoma, Unspecified Trial in Hangzhou (Anti CD30 CAR-T Cell Injection)

    Not yet recruiting
    • Hodgkin Lymphoma
    • +7 more
    • Anti CD30 CAR-T Cell Injection
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, College of medicine, Zhejiang Uni
    Jan 12, 2022

    Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory Trial in United States (CD30.CAR-T, Fludarabine,

    Active, not recruiting
    • Hodgkin Lymphoma, Adult
    • +3 more
    • Duarte, California
    • +4 more
    Apr 3, 2022

    Brentuximab Vedotin Intravenous Infusion "Untreated

    Active, not recruiting
    • Untreated CD30-Positive Hodgkin's Lymphoma
    • Brentuximab vedotin (Genetical Recombination)
    • Tokyo, Japan
      Takeda Selected Site
    Mar 24, 2022

    Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma Trial in Houston (autologous CAR.CD30 EBV specific-CTLs)

    Active, not recruiting
    • Hodgkin's Lymphoma
    • Non-Hodgkin's Lymphoma
    • autologous CAR.CD30 EBV specific-CTLs
    • Houston, Texas
    • +1 more
    Feb 4, 2022

    B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,

    Not yet recruiting
    • B Acute Lymphoblastic Leukemia
    • +2 more
    • Azacitidine Injection
    • +2 more
    • (no location specified)
    Oct 15, 2023

    Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent Trial in United States (Nivolumab, Autologous

    Recruiting
    • Classical Hodgkin Lymphoma
    • +2 more
    • Duarte, California
    • +4 more
    Jun 27, 2022

    Recurrent Lymphoproliferative Disorder, Refractory Lymphoproliferative Disorder Trial in Duarte (Leflunomide)

    Active, not recruiting
    • Recurrent Lymphoproliferative Disorder
    • Refractory Lymphoproliferative Disorder
    • Duarte, California
      City of Hope Medical Center
    Jun 7, 2022